Clinical Trials
Plasma Metabolomic Signatures Predict Response and Survival in Advanced NSCLC
Gozalvez et alJournal for ImmunoTherapy of Cancer

In the prospective observational METLUNG study (ISRCTN98848959), researchers evaluated baseline plasma metabolomic profiling to determine its association with clinical response, progression-free survival (PFS), and overall survival (OS) in patients with advanced non-small cell lung cancer (NSCLC) receiving immune checkpoint inhibitor (ICI) regimens. The study evaluated 127 patients with stage III–IV disease, comprising 94 adenocarcinomas and 28 squamous cell carcinomas, treated with first-line ICI monotherapy (n=39), first-line chemo-immunotherapy (n=47), or second-line ICI therapy (n=41).
A clinical response, assessed via iRECIST alongside clinical and radiological trajectory, was achieved by 52.8% of patients. Univariate metabolomic profiling identified 41 baseline metabolites correlated with therapeutic response, 69 metabolites linked to PFS, and 71 metabolites linked to OS. Notably, five metabolites retained consistent prognostic significance across all clinical endpoints: higher baseline concentrations of histidine and citric acid were associated with favorable outcomes, whereas increased concentrations of uracil, lactic acid, and sarcosine correlated with unfavorable outcomes.
Multivariate survival modeling revealed that combining metabolomic data with clinical factors into an integrated composite model delivered superior prognostic discrimination, particularly for early survival, compared to models using clinical or metabolomic variables alone. Furthermore, within the subset of patients receiving first-line immunotherapy monotherapy, only the integrated clinical–metabolomic model maintained a statistically significant association with OS. The investigators noted that these findings are exploratory and require validation in independent, multicenter cohorts prior to clinical application.
Key Takeaways
- Five baseline plasma metabolites (histidine, citric acid, uracil, lactic acid, and sarcosine) consistently correlated with outcomes across endpoints in advanced NSCLC treated with immune checkpoint inhibitors, with elevated histidine and citric acid associating with improved outcomes, whereas elevated uracil, lactic acid, and sarcosine correlated with worse outcomes.
- An integrated clinical–metabolomic composite model outperformed standalone clinical or metabolomic models in early survival discrimination and was the only model to achieve statistical significance for overall survival in the immunotherapy monotherapy subgroup.
- Clinical response occurred in 52.8% of evaluable patients and differed significantly by sex and Eastern Cooperative Oncology Group performance status, showing no association with baseline PD-L1 expression or smoking history.
Read the original sourceJournal for ImmunoTherapy of Cancer
